Leerink Partners Upgrades AN2 Therapeutics (ANTX) to Outperform May 14, 2026 06:08AM
AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 6c May 11, 2026 05:04PM
AN2 Therapeutics enters $80 million share sale agreement with Jefferies Apr 9, 2026 05:07PM
AN2 Therapeutics, Inc. (ANTX) Misses Q4 EPS by 7c Mar 17, 2026 05:03PM
AN2 Therapeutics receives FDA clearance for M. abscessus lung disease trial Jan 12, 2026 07:06AM


Nov 10, 2025 07:00AM AN2 Therapeutics partners with GSK on tuberculosis drug development
Aug 12, 2025 05:15PM AN2 Therapeutics, Inc. (ANTX) Tops Q2 EPS by 10c
Aug 12, 2025 07:02AM AN2 Therapeutics begins human trial for Chagas disease drug
Jul 23, 2025 07:00AM AN2 Therapeutics partners with DNDi to develop Chagas disease treatment
Jun 30, 2025 07:02AM AN2 Therapeutics, Inc (ANTX) Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis
May 13, 2025 04:01PM AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 10c
May 5, 2025 04:05AM AN2 Therapeutics (ANTX) PT Lowered to $2 at Citizens JMP
May 1, 2025 04:00PM AN2 Therapeutics, Inc (ANTX) Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study
Mar 26, 2025 04:06AM Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Mar 26, 2025 01:46AM Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Mar 25, 2025 04:43PM AN2 Therapeutics, Inc. (ANTX) Tops Q4 EPS by 2c
Feb 25, 2025 04:08AM Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Feb 24, 2025 07:03AM AN2 Therapeutics, Inc (ANTX) Provides Strategic Update for Phase 3 EBO-301 Trial
Feb 20, 2025 04:07AM Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Feb 3, 2025 04:13AM JMP Securities Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Jan 28, 2025 05:42AM JMP Securities Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Nov 18, 2024 02:43AM TD Cowen Downgrades AN2 Therapeutics (ANTX) to Hold
Oct 17, 2024 07:03AM AN2 Therapeutics (ANTX) Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis and Malaria
Aug 16, 2024 07:02AM AN2 Therapeutics (ANTX) Adopts Limited Duration Stockholder Rights Plan
Aug 13, 2024 04:12PM AN2 Therapeutics, Inc. (ANTX) Tops Q2 EPS by 13c
Aug 9, 2024 08:37AM Evercore ISI Downgrades AN2 Therapeutics (ANTX) to Underperform
Aug 8, 2024 04:30PM AN2 Therapeutics, Inc (ANTX) Provides Update on EBO-301 Phase 2/3 Study of Epetraborole